Tango Therapeutics (TNGX) Expected to Announce Earnings on Wednesday

Tango Therapeutics (NASDAQ:TNGX) will likely be issuing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $41.3450 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 9:30 AM ET.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 79.72%. The firm had revenue of $3.18 million during the quarter, compared to analyst estimates of $6.41 million. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Stock Up 0.3%

Shares of TNGX stock opened at $7.79 on Wednesday. The company has a 50 day moving average price of $7.53 and a 200-day moving average price of $5.30. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $9.70. The firm has a market capitalization of $866.72 million, a PE ratio of -5.86 and a beta of 1.67.

Insiders Place Their Bets

In other Tango Therapeutics news, major shareholder Rock Ventures Iv L.P. Third sold 1,100,000 shares of Tango Therapeutics stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $7.01, for a total transaction of $7,711,000.00. Following the transaction, the insider owned 15,759,075 shares of the company’s stock, valued at $110,471,115.75. The trade was a 6.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 3,472,501 shares of company stock worth $26,350,320 over the last quarter. 7.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Tango Therapeutics

Large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in Tango Therapeutics by 68.1% during the second quarter. Rhumbline Advisers now owns 112,273 shares of the company’s stock valued at $575,000 after purchasing an additional 45,467 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Tango Therapeutics by 35.1% in the second quarter. Invesco Ltd. now owns 95,293 shares of the company’s stock worth $488,000 after buying an additional 24,776 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Tango Therapeutics by 270.6% in the first quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock worth $483,000 after buying an additional 257,668 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Tango Therapeutics by 113.5% in the second quarter. JPMorgan Chase & Co. now owns 66,675 shares of the company’s stock worth $341,000 after buying an additional 35,439 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Tango Therapeutics by 46.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,998 shares of the company’s stock worth $215,000 after buying an additional 13,360 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Analyst Upgrades and Downgrades

TNGX has been the topic of a number of research reports. Guggenheim raised their price objective on shares of Tango Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, October 24th. Piper Sandler initiated coverage on shares of Tango Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $11.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a report on Monday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.00.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.